| Contributed by Seungmi Lee, Partner at JNPMEDI
AI-Interpreted Diagnostic Results Are No Longer Unfamiliar in Hospitals
Only a few years ago, encountering AI-driven diagnostic results directly in a clinical setting felt like a distant future. Today, AI diagnostics, digital therapeutics, and wearable health devices have become part of our everyday medical landscape. As the boundaries between medicine and technology rapidly blur, laws and regulations can no longer remain in the past.
Innovation Moves Fast, Regulations Were Slow
The digital healthcare industry is experiencing explosive growth. Each month brings new AI diagnostic tools, digital therapeutics, health management apps, and wearables. Yet the legal framework that should support this innovation has lagged far behind. Existing pharmaceutical and medical device laws have struggled to accommodate emerging product categories such as AI software and digital convergence products.
This led to concerns that innovation was being constrained by regulation, while others warned of risks in allowing such products into the market without sufficient safeguards.
Against This Backdrop Emerged the โDigital Medical Products Actโ
Both government and industry agreed that traditional medical device laws had clear limitations in managing these new technologies. The Digital Medical Products Act is a โtailored regulatory frameworkโ designed to bring AI, software, wearables, and hybrid digital-pharmaceutical products under a unified system. It establishes product-specific standards for approval, review, and post-market managementโaiming to keep pace with innovation while ensuring safety.
The Act has drawn attention as a national priority aligned with President Lee Jae-myungโs agenda to cultivate the high-tech bio and digital healthcare industry. Since taking office, President Lee has emphasized regulatory innovation in digital healthcare and reinforcing global competitiveness, pledging practical reforms that reflect on-the-ground needs.
A Key Feature: The โChange Management Planโ System
For AI-based medical devices that are frequently updated, submitting a change plan in advance allows improvements to be made quickly within the approved scope without a separate review. This represents a meaningful step toward accelerating innovation while maintaining safety.
Starting in 2026, wellness productsโpreviously outside the scope of medical device regulationโwill also come under a formal life-cycle management framework that includes clinical evaluation, approval, quality control, and advertising requirements. This enhances consumer safety but also brings new challenges for industry.
Practical discussions are needed on how to classify products that range from simple health management tools to self-management solutions for chronic diseases, to those directly tied to diagnosis or treatment. Many advocate for risk-based categorization and continuous monitoring using real-world data rather than ending with pre-market approval alone.
Digital Medical Device Regulatory Innovation Is Accelerating Globally
The U.S. FDA is issuing new guidance for AI-based medical devices and software as a medical device, emphasizing algorithmic transparency, post-market monitoring, and data integrity.
The European Union will begin implementing the European Health Data Space (EHDS) in 2025, strengthening requirements for security, interoperability, and record management when medical devices interface with Electronic Health Records (EHR).
The WHO has also emphasized that while each country should develop digital health strategies suited to its own context, alignment with international standards is essential.
The Digital Medical Products Act Marks a New Starting Point for Balancing Innovation and Safety
Legislation alone cannot resolve all issues. As part of President Leeโs national agenda, the Act must be followed by:
โข Development of detailed technical guidelines
โข Restructuring of insurance reimbursement systems
โข Close communication with healthcare professionals
โข Alignment with global regulations
Now is the time for industry, healthcare, and regulatory bodies to work together to build a realistic and predictable regulatory framework and strategies for strengthening global competitiveness. This institutional innovation will set new standards for the future of digital medical devices and public health.
ย ๐ Reference: Invest News | invest(https://www.investnews.co.kr)ย
| Contributed by Seungmi Lee, Partner at JNPMEDI
AI-Interpreted Diagnostic Results Are No Longer Unfamiliar in Hospitals
Only a few years ago, encountering AI-driven diagnostic results directly in a clinical setting felt like a distant future. Today, AI diagnostics, digital therapeutics, and wearable health devices have become part of our everyday medical landscape. As the boundaries between medicine and technology rapidly blur, laws and regulations can no longer remain in the past.
Innovation Moves Fast, Regulations Were Slow
The digital healthcare industry is experiencing explosive growth. Each month brings new AI diagnostic tools, digital therapeutics, health management apps, and wearables. Yet the legal framework that should support this innovation has lagged far behind. Existing pharmaceutical and medical device laws have struggled to accommodate emerging product categories such as AI software and digital convergence products.
This led to concerns that innovation was being constrained by regulation, while others warned of risks in allowing such products into the market without sufficient safeguards.
Against This Backdrop Emerged the โDigital Medical Products Actโ
Both government and industry agreed that traditional medical device laws had clear limitations in managing these new technologies. The Digital Medical Products Act is a โtailored regulatory frameworkโ designed to bring AI, software, wearables, and hybrid digital-pharmaceutical products under a unified system. It establishes product-specific standards for approval, review, and post-market managementโaiming to keep pace with innovation while ensuring safety.
The Act has drawn attention as a national priority aligned with President Lee Jae-myungโs agenda to cultivate the high-tech bio and digital healthcare industry. Since taking office, President Lee has emphasized regulatory innovation in digital healthcare and reinforcing global competitiveness, pledging practical reforms that reflect on-the-ground needs.
A Key Feature: The โChange Management Planโ System
For AI-based medical devices that are frequently updated, submitting a change plan in advance allows improvements to be made quickly within the approved scope without a separate review. This represents a meaningful step toward accelerating innovation while maintaining safety.
Starting in 2026, wellness productsโpreviously outside the scope of medical device regulationโwill also come under a formal life-cycle management framework that includes clinical evaluation, approval, quality control, and advertising requirements. This enhances consumer safety but also brings new challenges for industry.
Practical discussions are needed on how to classify products that range from simple health management tools to self-management solutions for chronic diseases, to those directly tied to diagnosis or treatment. Many advocate for risk-based categorization and continuous monitoring using real-world data rather than ending with pre-market approval alone.
Digital Medical Device Regulatory Innovation Is Accelerating Globally
The U.S. FDA is issuing new guidance for AI-based medical devices and software as a medical device, emphasizing algorithmic transparency, post-market monitoring, and data integrity.
The European Union will begin implementing the European Health Data Space (EHDS) in 2025, strengthening requirements for security, interoperability, and record management when medical devices interface with Electronic Health Records (EHR).
The WHO has also emphasized that while each country should develop digital health strategies suited to its own context, alignment with international standards is essential.
The Digital Medical Products Act Marks a New Starting Point for Balancing Innovation and Safety
Legislation alone cannot resolve all issues. As part of President Leeโs national agenda, the Act must be followed by:
โข Development of detailed technical guidelines
โข Restructuring of insurance reimbursement systems
โข Close communication with healthcare professionals
โข Alignment with global regulations
Now is the time for industry, healthcare, and regulatory bodies to work together to build a realistic and predictable regulatory framework and strategies for strengthening global competitiveness. This institutional innovation will set new standards for the future of digital medical devices and public health.
ย ๐ Reference: Invest News | invest(https://www.investnews.co.kr)ย